{
    "nctId": "NCT00470301",
    "briefTitle": "Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer",
    "officialTitle": "A Phase I-II Study of R115777 (Tipifarnib, Zarnestra\u00ae) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Stage IIB-IIIC Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Pathologic Complete Response Rate (pCR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of the breast; clinical stage IIB, IIIA, IIIB, or IIIC disease\n* At least 1 week since prior tamoxifen or other selective estrogen receptor modulator for prevention or for other indications (e.g., osteoporosis or prior ductal carcinoma in situ)\n* HER-2/neu-negative by immunohistochemistry or fluorescence in situ hybridization (FISH)\n* Hormone receptor status:\n\n  * Estrogen and/or progesterone receptor-positive\\* \\[Note: \\*Patients enrolled on the phase I portion of the trial may have estrogen and progesterone receptor-negative disease\\]\n* Normal organ function including:\n* WBC \\>= 3,000/mm\\^3\n* Absolute neutrophil count \\>= 1,500/mm\\^3\n* Platelet count \\>= 100,000/mm\\^3\n* Bilirubin normal\n* AST and ALT =\\< 2.5 times upper limit of normal\n* LVEF normal by echocardiogram or nuclear scan\n* Creatinine normal OR Creatinine clearance \\>= 60 mL/min\n* FEV1 \\>= 1 L\\* and DLCO \\>= 50%\\* \\[Note: \\*Only if baseline CT scan of chest shows parenchymal lung disease OR there is a history of chronic obstructive or other pulmonary disease\\]\n* No prior chemotherapy, radiotherapy, or definitive therapeutic surgery (e.g., mastectomy, lumpectomy, or axillary dissection) for this cancer but prior sentinel lymph node biopsy for this malignancy allowed\n* No prior adjuvant chemotherapy for a previous breast malignancy\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No other concurrent investigational agents\n* No other concurrent anticancer agents or therapies\n* ECOG performance status 0-1\n* Fertile patients must use effective contraception\n\nExclusion criteria:\n\n* No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n* No history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other study drugs (e.g., imidazoles or quinolones)\n* No other uncontrolled illness including, but not limited to, any of the following: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would preclude study compliance\n* Not pregnant or nursing",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}